Araştırma Makalesi
PDF Zotero Mendeley EndNote BibTex Kaynak Göster

Retrospective Analysis of Patients Who Develop Cancer After Renal Transplantation: A 12-Year Experience in a Single Center

Yıl 2022, Cilt 44, Sayı 1, 28 - 30, 30.03.2022
https://doi.org/10.7197/cmj.1093501

Öz

Objective: Kidney transplantation is the best treatment option for patients with end-stage renal disease. However, renal transplant recipients have been shown to have a higher risk of cancer than the general population. This has been attributed to malignancies associated with immunosuppression in these patients. In our study, we aimed to investigate the incidence of post-transplant malignancy, duration of development and risk factors in kidney transplant recipients.
Method: 1029 patients who underwent kidney transplantation in our organ transplant clinic between January 2006 and December 2018 were analyzed retrospectively through their demographic data, immunosuppressive protocols, post-transplant cancer types, and cancer onset files.
Results: Cancer developed in a total of 21 recipients (2%). The donor of 89.5% of the cases was alive. There was a history of smoking in 64.3% of the cases, and a family history of cancer in 45.5%. The most common type of cancer was skin cancer (n: 4). Basal cell Ca in 2 cases with skin cancer, Kaposi sarcoma in 1 case, and Merkel Cell Ca in 1 case (Table 2). Two of our patients with lung cancer had a history of smoking. The family history of our 2 cases with gastric cancer was positive. However, no statistically significant difference was found between family history and smoking and cancer incidence (p=0.576)
Conclusions: As transplant recipients continue to live longer with improved outcomes, cancer will increase as a cause of morbidity and mortality in this population. More research is needed to understand whether tumors arising in this population are affected by the patient's immunosuppression.

Kaynakça

  • 1. Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, Hays R, Howard A, Jones E, Leichtman AB, et al. Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/kidney disease outcomes quality initiative (NKF/KDOQI™) conference. Clin J Am Soc Nephrol. 2008;3(2):471–80
  • 2. Jaesung H, Kyu Noh O, YoungTaek O, Chun M, Kim L. Cancer risk after renal transplantation in South Korea: a nationwide populationbased study. BMC Nephrol 2018 ;19(1):311.
  • 3. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010; 10:1889-1896.
  • 4. Zhou AY, Ryeom S. Cyclosporin A promotes tumor angiogenesis in a calcineurin-independent manner by increasing mitochondrial reactive oxygen species. Mol Cancer Res. 2014; 12:1663-1676.
  • 5. Wong G, Turner RM, Chapman JR, Howell M, Lim WH, Webster AC, Craig JC. Time on dialysis and cancer risk after kidney transplantation. Transplantation. 2013; 95(1):114–21.
  • 6. Hall EC, Pfeiffer RM, Segev DL, Engels EA. Cumulative incidence of cancer after solid organ transplantation. Cancer. 2013;119(12):2300-8.
  • 7. Kim HS, Seo YM, Park UJ, Kim HT, Cho WH, Hwang EA, Han SY, Park SB, Kim HC, Jang HS,et al. Crude incidence rateofmalignancyafter kidney transplantation. JKoreanSoc Transplant. 2010; 24(3):182–6.
  • 8. Ramsay HM1, Fryer AA, Hawley CM, Smith AG, Harden PN. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol. 2002 ;147(5):950-6.
  • 9. Naldi L1, Fortina AB, Lovati S, Barba A, Gotti E, Tessari G, Schena D, Diociaiuti A, Nanni G, La Parola IL, Masini C, Piaserico S, Peserico A, Cainelli T, Remuzzi G. Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registry-based study. Transplantation. 2000; 70(10):1479-84.
  • 10. Agraharkar ML1, Cinclair RD, Kuo YF, Daller JA, Shahinian VB. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int. 2004 ; 66(1):383-9.
  • 11. Ferlay J, Soerjomataram I, Ervik M, et al. Cancer incidence and mortality worldwide. IARC Cancer base No: 11. GLOBACAN 2012.https://publications.iarc.fr/Databases/IarcCancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012
  • 12. D'Arcy ME, Coghill AE, Lynch CF, Koch LA, Li J, Pawlish KS, Morris CR, Rao C, Engels EA .Survival After a Cancer Diagnosis Among Solid Organ Transplant Recipients in the United States. Cancer. 2019 Mar 15;125(6):933-942. doi: 10.1002/cncr.31782. Epub 2019 Jan 9.

Yıl 2022, Cilt 44, Sayı 1, 28 - 30, 30.03.2022
https://doi.org/10.7197/cmj.1093501

Öz

Kaynakça

  • 1. Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, Hays R, Howard A, Jones E, Leichtman AB, et al. Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/kidney disease outcomes quality initiative (NKF/KDOQI™) conference. Clin J Am Soc Nephrol. 2008;3(2):471–80
  • 2. Jaesung H, Kyu Noh O, YoungTaek O, Chun M, Kim L. Cancer risk after renal transplantation in South Korea: a nationwide populationbased study. BMC Nephrol 2018 ;19(1):311.
  • 3. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010; 10:1889-1896.
  • 4. Zhou AY, Ryeom S. Cyclosporin A promotes tumor angiogenesis in a calcineurin-independent manner by increasing mitochondrial reactive oxygen species. Mol Cancer Res. 2014; 12:1663-1676.
  • 5. Wong G, Turner RM, Chapman JR, Howell M, Lim WH, Webster AC, Craig JC. Time on dialysis and cancer risk after kidney transplantation. Transplantation. 2013; 95(1):114–21.
  • 6. Hall EC, Pfeiffer RM, Segev DL, Engels EA. Cumulative incidence of cancer after solid organ transplantation. Cancer. 2013;119(12):2300-8.
  • 7. Kim HS, Seo YM, Park UJ, Kim HT, Cho WH, Hwang EA, Han SY, Park SB, Kim HC, Jang HS,et al. Crude incidence rateofmalignancyafter kidney transplantation. JKoreanSoc Transplant. 2010; 24(3):182–6.
  • 8. Ramsay HM1, Fryer AA, Hawley CM, Smith AG, Harden PN. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol. 2002 ;147(5):950-6.
  • 9. Naldi L1, Fortina AB, Lovati S, Barba A, Gotti E, Tessari G, Schena D, Diociaiuti A, Nanni G, La Parola IL, Masini C, Piaserico S, Peserico A, Cainelli T, Remuzzi G. Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registry-based study. Transplantation. 2000; 70(10):1479-84.
  • 10. Agraharkar ML1, Cinclair RD, Kuo YF, Daller JA, Shahinian VB. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int. 2004 ; 66(1):383-9.
  • 11. Ferlay J, Soerjomataram I, Ervik M, et al. Cancer incidence and mortality worldwide. IARC Cancer base No: 11. GLOBACAN 2012.https://publications.iarc.fr/Databases/IarcCancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012
  • 12. D'Arcy ME, Coghill AE, Lynch CF, Koch LA, Li J, Pawlish KS, Morris CR, Rao C, Engels EA .Survival After a Cancer Diagnosis Among Solid Organ Transplant Recipients in the United States. Cancer. 2019 Mar 15;125(6):933-942. doi: 10.1002/cncr.31782. Epub 2019 Jan 9.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Bilimleri ve Hizmetleri
Bölüm Dahili Tıp Bilimleri Araştırma Yazıları
Yazarlar

Mesut DEMİR (Sorumlu Yazar)
hamidiye etfal eğitim ve araştırma hastanesi
0000-0002-4728-056X
Türkiye


İlhami BARLAS
Istanbul Bilim University Florence Nightingale Hospital
0000-0003-0422-4960
Türkiye

Yayımlanma Tarihi 30 Mart 2022
Yayınlandığı Sayı Yıl 2022, Cilt 44, Sayı 1

Kaynak Göster

APA Demir, M. & Barlas, İ. (2022). Retrospective Analysis of Patients Who Develop Cancer After Renal Transplantation: A 12-Year Experience in a Single Center . Cumhuriyet Medical Journal , 44 (1) , 28-30 . DOI: 10.7197/cmj.1093501